{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:50:54Z","timestamp":1787017854622,"version":"build-2736575974"},"reference-count":15,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>The real-world effectiveness of the bispecific antibody teclistamab seems to be lower than the efficacy observed in pivotal registration trials. Understanding the drivers of this effectiveness\u2013efficacy gap is essential for guiding the rational selection of patients most likely to benefit, optimizing bispecific antibody therapy in high-risk populations and ultimately advancing more personalized treatment strategies while supporting sustainable models of care.<\/jats:p>\n                  <jats:p>See related article by Razzo et al., p. 561<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-25-0292","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:20:14Z","timestamp":1758118814000},"page":"542-546","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands."},{"name":"2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-9550","authenticated-orcid":false,"given":"Febe","family":"Smits","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands."},{"name":"2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands."},{"name":"3Haga Ziekenhuis, Den Haag, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands."},{"name":"2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2025110303135518700_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110303135518700_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/2643-3230.BCD-24-0354","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the U.S. Myeloma Immunotherapy Consortium","volume":"6","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2025110303135518700_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"2025110303135518700_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"2025110303135518700_bib5","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"key":"2025110303135518700_bib6","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"2025110303135518700_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood.2023020327","article-title":"Equality: trial and error?","volume":"142","author":"Cucchi","year":"2023","journal-title":"Blood"},{"key":"2025110303135518700_bib8","first-page":"228","article-title":"Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study","volume":"110","author":"Visram","year":"2025","journal-title":"Haematologica"},{"key":"2025110303135518700_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMp2416479","article-title":"The promise of real-world data for research - what are we missing?","volume":"393","author":"Abbasi","year":"2025","journal-title":"N Engl J Med"},{"key":"2025110303135518700_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"2025110303135518700_bib11","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","article-title":"Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution","volume":"9","author":"Riedel","year":"2025","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2025110303135518700_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2022-157767","article-title":"No evidence of BCMA expression loss or systemic immune impairment after treatment with the BCMA-targeted antibody-drug conjugate (ADC) belantamab mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 trials of patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Lowther","year":"2022","journal-title":"Blood"},{"key":"2025110303135518700_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"2025110303135518700_bib14","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network","volume":"12","author":"van de Donk","year":"2025","journal-title":"Lancet Haematol"},{"key":"2025110303135518700_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0292\/3651699\/bcd-25-0292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0292\/3652078\/bcd-25-0292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/542\/3663374\/bcd-25-0292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/542\/3663374\/bcd-25-0292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:14:05Z","timestamp":1762157645000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/542\/766816\/The-Two-Sides-of-Bispecific-Antibodies-in-Multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,19]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0292","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}